ClinicalTrials.gg
CompletedNCT07394309Updated Aug 13, 2026

Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls

A Phase 1 interventional study of Hydronidone capsules in Liver Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
107th of 127
30 · median 120
Started
2026
with 19 others
Phase 1
11 of 214
2 open now
Registered
193rd of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 107th largest by enrollment of the 127 interventional ones that give a count, is one of 20 that started in 2026, is one of 11 in phase 1, and was the 193rd registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal hepatic function matched for sex, age, and BMI. The administration method is a single oral dose of 90 mg hydroxynidone capsules under fasting conditions.

Participants meeting the inclusion criteria with corresponding degrees of hepatic impairment and those with normal hepatic function will be enrolled. Each group will complete the study with 10 participants. Matched participants will be comparable in terms of sex (±1 participant per sex), mean age (±10 years), and mean BMI (±10%).

03

Conditions studied

  • Liver Fibrosis

Browse trials for

Keywords

  • Hydronidone
  • Liver Fibrosis
  • Patients with hepatic fibrosis due to chronic hepatitis B
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria to be eligible for enrollment:
  • Participants fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign a written form, and are able to complete the entire trial process as required by the protocol.
  • Age between 18 and 75 years (inclusive), both males and females.
  • At screening, male participants weigh ≥50 kg, female participants weigh ≥45 kg, and [BMI = weight (kg) / height² (m²)] is within the range of 18 to 32 kg/m² (inclusive).
  • Participants and their partners agree to have no plans for conception or sperm/egg donation from the signing of the informed consent form until 6 months after the last dose of the drug, and voluntarily agree to use effective measures.
  • Participants with hepatic impairment must additionally meet the following inclusion criteria:

Participants with hepatic impairment due to pre-existing primary liver disease, classified as Class A (score of 5-6) or Class B (score of 7-9) at screening. They must not have received albumin infusion within 14 days prior to screening and must have a confirmed diagnosis of stable (≥1 month) hepatic impairment based on medical history, physical examination, laboratory tests, or imaging studies.

Participants have not taken any medication within 1 week prior to screening, or for those requiring long-term treatment for hepatic impairment and/or other comorbidities, their medication regimen must have been stable for at least 4 weeks (stability is judged by the investigator, excluding medications prohibited by the protocol).

Exclusion criteria

Exclusion Criteria:

  • Known history of allergy to any component of the product, drugs of the same class (GLP-1 receptor agonists), or their ; or history of allergic constitution (multiple drug and food allergies); or history of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.).
  • Diagnosis of malignant tumor, or history of malignant tumor within 5 years prior to screening (except for: prior hepatocellular carcinoma surgery with stability ≥2 years; treated non-melanoma skin cancer with no signs of recurrence; and excised cervical intraepithelial neoplasia).
  • Presence of severe infection, trauma, gastrointestinal surgery, or other major surgery within 4 weeks prior to screening.
  • 12-lead (ECG) abnormalities considered by the investigator [e.g., tachycardia/bradycardia requiring medication, II-III degree atrioventricular block, prolonged interval (male QTcF >470 ms, female QTcF >480 ms, corrected using Fridericia's formula), or other abnormalities deemed clinically significant by the physician].
  • Estimated (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula \<60 mL/min/1.73 m².
  • Planned surgical procedure or hospitalization tendency during the trial period.
  • Positive for antibody (HIV-Ab) or Treponema pallidum (TP) antibody.
  • Use of inducers or inhibitors of drug-metabolizing enzymes ( inducers and inhibitors, detailed list in Appendix 4: Common Drugs that are Inhibitors or Inducers of Drug-Metabolizing Enzymes) within 4 weeks prior to dosing.
  • Use of drugs known to inhibit or induce SULT and UGT enzymes within 7 days prior to investigational drug administration, and inability to discontinue such use.
  • Use of any medication (including herbal medicines, vitamins, health supplements) within 14 days (or 5 half-lives, whichever is longer) prior to dosing, except for stable medications in participants with hepatic impairment.
  • Participation in another clinical trial and receipt of an investigational drug or medical device within 1 month prior to screening, with the last dose date of the previous clinical study as the reference point (if the previous investigational drug has a long half-life, at least 5 half-lives must elapse before dosing in this study).
  • History of blood loss or blood donation ≥400 mL within 3 months prior to dosing, or plans to donate blood within 1 month after the end of this trial.
  • History of smoking or smoking more than 5 cigarettes per day within 3 months prior to screening, or inability to abstain from any tobacco products during the study, or positive nicotine test at baseline.
  • Regular alcohol consumption at present or within 1 month prior to screening, defined as females consuming more than 7 units of alcohol per week or males consuming more than 14 units of alcohol per week (1 unit = 285 mL of beer, or 25 mL of spirits with 40% alcohol, or 100 mL of wine); or positive alcohol breath test at baseline, or inability to abstain from alcohol during the trial.
  • History of drug abuse, or use of soft drugs (e.g., marijuana) within 3 months prior to dosing, or use of hard drugs (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year prior to dosing, or positive drug abuse screening at baseline.
  • Consumption of food or beverages containing grapefruit juice/pomelo juice or methylxanthines (tea, coffee, cola, chocolate, energy drinks) within 48 hours prior to dosing, or consumption of any other substance that may affect drug absorption, distribution, metabolism, or excretion.
  • Intolerance to venipuncture, history of needle phobia, or fainting at the sight of blood.
  • Vaccination within 1 month prior to screening.
  • Women who are pregnant or breastfeeding, or participants with a positive blood pregnancy test.
  • Participants considered by the investigator to have poor compliance or other factors unsuitable for participation in this trial.
  • Supplementary Exclusion Criteria for Participants with Hepatic Impairment (Exclusion if any one of the following criteria is met):

History of liver transplantation.

Drug-induced liver injury.

Acute liver injury due to any cause.

Cholestatic liver disease.

Liver failure with any of the following complications: uncontrolled infection; grade 3/4 hepatic encephalopathy.

Severe complications of cirrhosis with any of the following: active bleeding from esophageal or gastric varices; severe/advanced ascites or pleural effusion requiring paracentesis or drainage and albumin supplementation; hepatorenal syndrome; or any other condition deemed by the investigator as unsuitable for study participation.

Participants with poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg) or heart rate >120 bpm (allow two repeat measurements).

Any history of severe disease other than the primary liver disease itself, or any medical history or clinically significant abnormal laboratory findings considered by the investigator as likely to affect the trial results, including but not limited to history of circulatory, endocrine, neurological, digestive, urinary, hematological, immunological, psychiatric, or metabolic disorders.

(ALT) and/or aspartate aminotransferase (AST) >5 times the (ULN) at screening.

Supplementary Exclusion Criteria for Participants with Normal Hepatic Function (Exclusion if any one of the following criteria is met):

Positive for anti- virus (HCV) antibody or surface antigen (HBsAg).

History of primary disease of vital organs, including but not limited to neurological/psychiatric, cardiovascular, gastrointestinal, respiratory, urinary, endocrine, hematological, or immune system diseases, deemed by the investigator as unsuitable for trial participation.

History of hepatic impairment, or any screening examination results (including physical examination, vital signs, complete blood count, urinalysis, blood biochemistry, coagulation function, 12-lead ECG, chest X-ray posteroanterior view, abdominal ultrasound, etc.) considered by the investigator as clinically significant abnormalities.

Age not within the range of the mean age of participants with mild/moderate hepatic impairment ±10 years, and/or not within the range of the mean BMI of participants with mild/moderate hepatic impairment ±10%.

-Supplementary Exclusion Criteria for Participants with Normal Hepatic Function (Exclusion if any one of the following criteria is met):

Positive for anti-hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg).

History of primary disease of vital organs, including but not limited to neurological/psychiatric, cardiovascular, gastrointestinal, respiratory, urinary, endocrine, hematological, or immune system diseases, deemed by the investigator as unsuitable for trial participation.

History of hepatic impairment, or any screening examination results (including physical examination, vital signs, complete blood count, urinalysis, blood biochemistry, coagulation function, 12-lead ECG, chest X-ray posteroanterior view, abdominal ultrasound, etc.) considered by the investigator as clinically significant abnormalities.

Age not within the range of the mean age of participants with mild/moderate hepatic impairment ±10 years, and/or BMI not within the range of the mean BMI of participants with mild/moderate hepatic impairment ±10%.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group One A(mild hepatic impairment group)

    10 participants with mild hepatic impairment (Child-Pugh A, score 5-6).

    Drug: Hydronidone capsules

  • Experimental
    Group Two B(moderate hepatic impairment group)

    10 participants with moderate hepatic impairment (Child-Pugh Class B, score of 7-9).

    Drug: Hydronidone capsules

  • Experimental
    Group Three C(control group, normal hepatic function group)

    Matched 10 healthy participants with normal hepatic function will serve as the control group.

    Drug: Hydronidone capsules

Interventions

  • A single oral dose of 90 mg of the investigational drug (3 Hydronidone capsules) under fasting conditions, administered with 240 mL of water.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter of Hydronidone: Cmax

    Time frame: Within 48 hours of administration

  2. Pharmacokinetic Parameter of Hydronidone: AUC0-t

    Time frame: Within 48 hours of administration

  3. Pharmacokinetic Parameter of Hydronidone:AUC0-∞

    Time frame: Within 48 hours of administration

  4. Pharmacokinetic Parameter of Hydronidone:Tmax

    Time frame: Within 48 hours of administration

  5. Pharmacokinetic Parameter of Hydronidone:t1/2

    Time frame: Within 48 hours of administration

  6. Pharmacokinetic Parameter of Hydronidone:λz

    Time frame: Within 48 hours of administration

  7. Pharmacokinetic Parameter of Hydronidone:CL/F

    Time frame: Within 48 hours of administration

  8. Pharmacokinetic Parameter of Hydronidone:MRT

    Time frame: Within 48 hours of administration

  9. Pharmacokinetic Parameter of Hydronidone:Vz/F

    Time frame: Within 48 hours of administration

  10. Pharmacokinetic Parameter of Hydronidone:Ratio of free drugsRatio of free drugs

    Time frame: Within 48 hours of administration

  11. Difference in the main parameters AUC₀-t between patients with hepatic impairment and participants with normal hepatic function.

    Time frame: Within 48 hours of administration

  12. Difference in the main parameters AUC₀-∞ between patients with hepatic impairment and participants with normal hepatic function.

    Time frame: Within 48 hours of administration

  13. Difference in the main parameters Cmax between patients with hepatic impairment and participants with normal hepatic function.

    Time frame: Within 48 hours of administration

Secondary outcomes

  1. Plasma Pharmacokinetic Parameters of Metabolites M3 and M4: Cmax (Metabolic Ratio).

    Time frame: Within 48 hours after administration

  2. Plasma Pharmacokinetic Parameters of Metabolites M3 and M4: AUC₀-t, (Metabolic Ratio).

    Time frame: Within 48 hours after administration

  3. Plasma Pharmacokinetic Parameters of Metabolites M3 and M4: MR (Metabolic Ratio).

    Time frame: Within 48 hours after administration

  4. Plasma Pharmacokinetic Parameters of Metabolites M3 and M4: AUC₀-∞, (Metabolic Ratio).

    Time frame: Within 48 hours after administration

  5. Plasma Pharmacokinetic Parameters of Metabolites M3 andM4:Tmax(Metabolic Ratio).

    Time frame: Within 48 hours after administration

  6. Plasma Pharmacokinetic Parameters of Metabolites M3 and M4: t₁/₂(Metabolic Ratio).

    Time frame: Within 48 hours after administration

07

Study locations

1 site
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in May 2026, 1 month.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
Mar 25, 2026
Primary completionActual
May 11, 2026
CompletionActual
May 11, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07394309
Collaborators
The First Affiliated Hospital of Bengbu Medical University
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Mar 25, 2026
Primary completion
May 11, 2026
Completion
May 11, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion